Exagen Financial Statements From 2010 to 2025

XGN Stock  USD 3.62  0.06  1.69%   
Exagen financial statements provide useful quarterly and yearly information to potential Exagen Inc investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Exagen financial statements helps investors assess Exagen's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Exagen's valuation are summarized below:
Gross Profit
33.1 M
Profit Margin
(0.27)
Market Capitalization
63.7 M
Enterprise Value Revenue
1.1722
Revenue
55.6 M
We have found one hundred twenty available fundamental signals for Exagen Inc, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to verify Exagen's prevailing fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 18th of March 2025, Market Cap is likely to grow to about 78.4 M, while Enterprise Value is likely to drop about 29.5 M.

Exagen Total Revenue

34.58 Million

Check Exagen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Exagen's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Interest Expense of 2.8 M or Total Revenue of 34.6 M, as well as many indicators such as Price To Sales Ratio of 1.33, Dividend Yield of 0.0169 or PTB Ratio of 8.21. Exagen financial statements analysis is a perfect complement when working with Exagen Valuation or Volatility modules.
  
Check out the analysis of Exagen Correlation against competitors.

Exagen Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets53.8 M44.7 M42.7 M
Slightly volatile
Short and Long Term Debt TotalM3.2 M16.8 M
Slightly volatile
Other Current Liabilities4.3 M7.8 M3.5 M
Slightly volatile
Total Current Liabilities9.8 M13.5 M10.4 M
Very volatile
Property Plant And Equipment Net4.2 M7.7 M3.3 M
Slightly volatile
Current Deferred Revenue3.4 M2.3 M2.7 M
Very volatile
Accounts Payable2.3 M4.1 M1.9 M
Slightly volatile
Cash35.9 M22 M27.8 M
Slightly volatile
Non Current Assets Total10.1 M8.2 M8.9 M
Slightly volatile
Cash And Short Term Investments35.9 M22 M27.8 M
Slightly volatile
Common Stock Shares Outstanding19.1 M18.2 M7.1 M
Slightly volatile
Liabilities And Stockholders Equity53.8 M44.7 M42.7 M
Slightly volatile
Non Current Liabilities Total20.6 M21.6 M17.1 M
Slightly volatile
Other Current Assets6.9 M6.6 MM
Slightly volatile
Other Stockholder Equity178.7 M303.9 M143.5 M
Slightly volatile
Total Liabilities34.1 M35.1 M27.7 M
Slightly volatile
Property Plant And Equipment Gross14.4 M13.7 M4.7 M
Slightly volatile
Total Current Assets43.7 M36.5 M33.8 M
Slightly volatile
Short Term Debt1.4 M1.5 M4.1 M
Slightly volatile
Common Stock14.8 K18 K13.1 K
Slightly volatile
Other Assets894.3 K475.2 K880.8 K
Pretty Stable
Net Receivables6.3 M7.8 M3.7 M
Slightly volatile
Property Plant Equipment15.8 M15 M4.8 M
Slightly volatile
Other Liabilities16.2 K17.1 K1.3 M
Slightly volatile
Net Working Capital21.8 M22.9 M28.9 M
Slightly volatile
Capital Stock17.1 K18 K59.2 M
Slightly volatile

Exagen Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.1 M1.7 M889.6 K
Slightly volatile
Interest Expense2.8 M2.2 M2.3 M
Slightly volatile
Total Revenue34.6 M55.6 M27.5 M
Slightly volatile
Other Operating Expenses50.7 M69.3 M41 M
Slightly volatile
Research Development3.8 M5.4 M3.1 M
Slightly volatile
Cost Of Revenue16.2 M22.5 M13.2 M
Slightly volatile
Total Operating Expenses34.5 M46.7 M27.8 M
Slightly volatile
Interest Income947.5 K767 K908.5 K
Very volatile
Selling General Administrative32 M41.4 M24.5 M
Slightly volatile
Reconciled Depreciation1.2 M1.7 M929.3 K
Slightly volatile
Selling And Marketing ExpensesM1.7 M1.7 M
Slightly volatile

Exagen Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation1.8 M1.8 M1.3 M
Slightly volatile
Begin Period Cash Flow34.5 M36.7 M26.4 M
Slightly volatile
DepreciationM1.7 M857.5 K
Slightly volatile
Capital Expenditures489.2 K515 K853.6 K
Slightly volatile
End Period Cash Flow36 M22.2 M27.9 M
Slightly volatile
Change To Netincome14.3 M13.6 M6.6 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.331.34131.4188
Slightly volatile
Dividend Yield0.01690.0190.0207
Slightly volatile
Days Sales Outstanding38.1651.396931.9687
Slightly volatile
Stock Based Compensation To Revenue0.04040.03170.0565
Slightly volatile
Capex To Depreciation0.280.29870.968
Very volatile
EV To Sales1.251.00251.336
Pretty Stable
Inventory Turnover17.039.2519.7858
Slightly volatile
Days Of Inventory On Hand21.0640.8421.5318
Slightly volatile
Payables Turnover5.845.44577.0544
Pretty Stable
Sales General And Administrative To Revenue1.511.011.7944
Slightly volatile
Research And Ddevelopement To Revenue0.09180.09660.3041
Slightly volatile
Capex To Revenue0.00880.00930.1143
Slightly volatile
Cash Per Share1.151.210668.0528
Slightly volatile
Days Payables Outstanding62.2767.024957.1329
Slightly volatile
Income Quality0.60.87850.7563
Pretty Stable
Current Ratio3.722.69924.0713
Slightly volatile
Receivables Turnover6.757.101628.4642
Slightly volatile
Capex Per Share0.02690.02835.4093
Slightly volatile
Revenue Per Share2.93.0567126
Pretty Stable
Interest Debt Per Share0.280.2976153
Slightly volatile
Debt To Assets0.06770.07120.5373
Slightly volatile
Operating Cycle54.5451.396947.1441
Slightly volatile
Days Of Payables Outstanding62.2767.024957.1329
Slightly volatile
Ebt Per Ebit1.61.10761.5329
Very volatile
Total Debt To Capitalization0.240.25021.2216
Pretty Stable
Quick Ratio3.642.69923.9878
Slightly volatile
Net Income Per E B T1.11.00081.0062
Slightly volatile
Cash Ratio3.11.63163.383
Slightly volatile
Days Of Inventory Outstanding21.0640.8421.5318
Slightly volatile
Days Of Sales Outstanding38.1651.396931.9687
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.851.03881.0453
Pretty Stable
Fixed Asset Turnover9.297.241210.666
Slightly volatile
Debt Ratio0.06770.07120.5373
Slightly volatile
Price Sales Ratio1.331.34131.4188
Slightly volatile
Asset Turnover1.311.24510.7176
Slightly volatile

Exagen Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap78.4 M74.6 M47.4 M
Slightly volatile
Enterprise Value29.5 M55.8 M36.3 M
Slightly volatile

Exagen Fundamental Market Drivers

Cash And Short Term Investments22 M

Exagen Upcoming Events

18th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
18th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Exagen Financial Statements

Exagen investors utilize fundamental indicators, such as revenue or net income, to predict how Exagen Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue2.3 M3.4 M
Total Revenue55.6 M34.6 M
Cost Of Revenue22.5 M16.2 M
Stock Based Compensation To Revenue 0.03  0.04 
Sales General And Administrative To Revenue 1.01  1.51 
Research And Ddevelopement To Revenue 0.10  0.09 
Capex To Revenue 0.01  0.01 
Revenue Per Share 3.06  2.90 
Ebit Per Revenue(0.25)(0.26)

Pair Trading with Exagen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Exagen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Exagen will appreciate offsetting losses from the drop in the long position's value.

Moving against Exagen Stock

  0.36VALN Valneva SE ADR Earnings Call TodayPairCorr
  0.33DVAX Dynavax TechnologiesPairCorr
  0.31DRMA Dermata TherapeuticsPairCorr
The ability to find closely correlated positions to Exagen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Exagen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Exagen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Exagen Inc to buy it.
The correlation of Exagen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Exagen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Exagen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Exagen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Exagen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Exagen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Exagen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Exagen Inc Stock:
Check out the analysis of Exagen Correlation against competitors.
You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.83)
Revenue Per Share
3.057
Quarterly Revenue Growth
(0.01)
Return On Assets
(0.17)
Return On Equity
(0.94)
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.